Triochem Products Fair Value
Triochem Products (TRIPR) average fair value is ₹4365.48 across 2 valuation models — P/E Based Valuation, Price-to-Sales Valuation, vs a current market price of ₹17.39 (+25003.36%), fair value range ₹2086.8–₹6644.15.
Fair Value Analysis Export
TRIPR Fair Value vs Current Price — Valuation Summary
TRIPR average fair value, fair value range, price gap and valuation status across 2 models: P/E Based Valuation, Price-to-Sales Valuation. Check Triochem Products market worth to track the company's total market size over time.
P/E Based Valuation
Price-to-Sales Valuation
TRIPR Fair Value Analysis — Data Sources & Coverage
Triochem Products financial data sources, valuation methods applied and sector benchmarks used. For live price and a broader fundamental view, visit TRIPR share price screener.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
TRIPR vs Healthcare Sector Peers — P/E, P/B & Market Cap
Triochem Products P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Jeena Sikho Lifecare | JSLL | 27.19 | 13.76 | ₹6,314 |
| Kerala Ayurveda | KERALAYUR | -7.9 | 18.27 | ₹225 |
| Sat Kartar Life | SATKARTAR | 11.08 | 2.77 | ₹191 |
| Sun Pharmaceutical | SUNPHARMA | 38.12 | 5.53 | ₹463,072 |
| Aurobindo Pharma | AUROPHARMA | 25.95 | 2.54 | ₹93,821 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.